Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus

被引:86
作者
Aquaro, S
Bagnarelli, P
Guenci, T
De Luca, A
Clementi, M
Balestra, E
Caliò, R
Perno, CF
机构
[1] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-100133 Rome, Italy
[2] Univ Ancona, Dept Microbiol, Ancona, Italy
[3] IRCCS L Spallanzani, Rome, Italy
[4] Univ Sacred Heart, Dept Infect Dis, I-00168 Rome, Italy
[5] Univ Vita Salute San Raffaele, Cattedra Microbiol, Milan, Italy
关键词
reservoir; viral dynamics; antiretroviral therapy; pathogenesis; HIV;
D O I
10.1002/jmv.10245
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The role of macrophages in the pathogenesis and progression of human immunodeficiency virus (HIV)-related infection is substantiated by in vitro and in vivo evidence. The unique ability to survive HIV infection and produce viral particles for long periods is postulated. Detailed studies of this phenomenon are lacking. The dynamics of HIV-1 replication and cumulative virus production was studied in long-term cultures of macrophages in the presence or in the absence of antiviral drugs. Multiply spliced and unspliced HIV-RNA production was assessed by quantitative PCR, and the number of infected cells was monitored by FACS analysis. Cumulative HIV-1 production was determined by a trapezoidal equation, including such parameters as times of collection and experimental values of genomic-RNA and p24 gag antigen. Unspliced and multiply spliced HIV-RNA increased linearly after macrophage infection; reached levels of 1.5 x 10(8) and 2.8 x 10(5) copies/ 10(5) cells, respectively, at day 10; and then remained stable throughout the course of the experiment. Cumulative production of genomic-RNA and p24 gag antigen was 10(10) copies/10(6) cells and 10(7) pg/10(6) cells, respectively, with an average of >200 virus particles produced daily by each macrophage. AZT decreased the cumulative production of both genomic-RNA and p24 gag antigen down to 2.5 x 10(9) copies and 1.1 x 10(6) pg/ 10(6) cells (73.8% and 88.9% inhibition, respectively) up to day 50 without virus breakthrough. Ritonavir had a limited, but consistent, efficacy on the release of mature virus proteins (about 40% inhibition), but not on HIV-RNA production. In conclusion, the long-term dynamics and the high cumulative virus production that characterize HIV-1 infection of macrophages underscore the peculiar role of these cells as a persistently infected reservoir of HIV. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:479 / 488
页数:10
相关论文
共 52 条
  • [21] EFFICIENT ISOLATION AND PROPAGATION OF HUMAN IMMUNODEFICIENCY VIRUS ON RECOMBINANT COLONY-STIMULATING FACTOR-1-TREATED MONOCYTES
    GENDELMAN, HE
    ORENSTEIN, JM
    MARTIN, MA
    FERRUA, C
    MITRA, R
    PHIPPS, T
    WAHL, LA
    LANE, HC
    FAUCI, AS
    BURKE, DS
    SKILLMAN, D
    MELTZER, MS
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (04) : 1428 - 1441
  • [22] Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
    Hatano, H
    Vogel, S
    Yoder, C
    Metcalf, JA
    Dewar, R
    Davey, RT
    Polis, MA
    [J]. AIDS, 2000, 14 (10) : 1357 - 1363
  • [23] Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4
    Herbein, G
    Mahlknecht, U
    Batliwalla, F
    Gregersen, P
    Pappas, T
    Butler, J
    O'Brien, WA
    Verdin, E
    [J]. NATURE, 1998, 395 (6698) : 189 - 194
  • [24] Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV):: Implications for HIV-1 infections of humans
    Igarashi, T
    Brown, CR
    Endo, Y
    Buckler-White, A
    Plishka, R
    Bischofberger, N
    Hirsch, V
    Martin, MA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (02) : 658 - 663
  • [25] HIV-1 IN BLOOD MONOCYTES - FREQUENCY OF DETECTION OF PROVIRAL DNA USING PCR AND COMPARISON WITH THE TOTAL CD4 COUNT
    INNOCENTI, P
    OTTMANN, M
    MORAND, P
    LECLERCQ, P
    SEIGNEURIN, JM
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) : 261 - 268
  • [26] ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS
    KEMPF, DJ
    MARSH, KC
    DENISSEN, JF
    MCDONALD, E
    VASAVANONDA, S
    FLENTGE, CA
    GREEN, BE
    FINO, L
    PARK, CH
    KONG, XP
    WIDEBURG, NE
    SALDIVAR, A
    RUIZ, L
    KATI, WM
    SHAM, HL
    ROBINS, T
    STEWART, KD
    HSU, A
    PLATTNER, JJ
    LEONARD, JM
    NORBECK, DW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) : 2484 - 2488
  • [27] DETECTION OF AIDS VIRUS IN MACROPHAGES IN BRAIN-TISSUE FROM AIDS PATIENTS WITH ENCEPHALOPATHY
    KOENIG, S
    GENDELMAN, HE
    ORENSTEIN, JM
    DALCANTO, MC
    PEZESHKPOUR, GH
    YUNGBLUTH, M
    JANOTTA, F
    AKSAMIT, A
    MARTIN, MA
    FAUCI, AS
    [J]. SCIENCE, 1986, 233 (4768) : 1089 - 1093
  • [28] Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114
  • [29] Langmann P, 2000, Eur J Med Res, V5, P59
  • [30] Indinavir population pharmacokinetics in plasma and cerebrospinal fluid
    Letendre, SL
    Cappirelli, EV
    Ellis, RJ
    McCutchan, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) : 2173 - 2175